Abstract
Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.
| Original language | English (US) |
|---|---|
| Article number | 34 |
| Journal | Current Treatment Options in Neurology |
| Volume | 21 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2019 |
Fingerprint
Keywords
- Clemastine
- GSK239512
- Multiple sclerosis
- Oligodendrocyte precursor cell
- Opicinumab
- Remyelination
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Approaches to Remyelination Therapies in Multiple Sclerosis. / Wooliscroft, Lindsey; Silbermann, Elizabeth; Cameron, Michelle; Bourdette, Dennis.
In: Current Treatment Options in Neurology, Vol. 21, No. 7, 34, 01.07.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Approaches to Remyelination Therapies in Multiple Sclerosis
AU - Wooliscroft, Lindsey
AU - Silbermann, Elizabeth
AU - Cameron, Michelle
AU - Bourdette, Dennis
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.
AB - Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.
KW - Clemastine
KW - GSK239512
KW - Multiple sclerosis
KW - Oligodendrocyte precursor cell
KW - Opicinumab
KW - Remyelination
UR - http://www.scopus.com/inward/record.url?scp=85068065911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068065911&partnerID=8YFLogxK
U2 - 10.1007/s11940-019-0574-1
DO - 10.1007/s11940-019-0574-1
M3 - Review article
AN - SCOPUS:85068065911
VL - 21
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
SN - 1092-8480
IS - 7
M1 - 34
ER -